Reuters
Published Jan 12, 2022 01:07AM ET
SEOUL (Reuters) -South Korea is turning to additional pharmaceutical tools as it looks to pre-empt a surge of COVID-19 omicron infections, authorising the use of Novavax (NASDAQ:NVAX) Inc's vaccine on Wednesday and preparing to distribute the first of Pfizer (NYSE:PFE)'s antiviral pills.
At least 21,000 of Pfizer's antiviral pills, called Paxlovid, will arrive in South Korea on Thursday, with another 10,000 more expected to arrive by the end of the month, the health ministry said.
The pills, which were authorised for emergency use in December, will begin being used in treatments for more than 1,000 people per day starting on Friday, the ministry added
"By priority, oral treatment is planned to begin first for patients aged 65 or older, or patients with reduced immunity at home and residential treatment centres," a ministry spokesperson told a briefing.
Paxlovid was nearly 90% effective in preventing hospitalizations and deaths in patients at high risk of severe illness, according to data from the company's clinical trial. Recent lab data suggests the drug retains its effectiveness against Omicron, Pfizer has said.
South Korea's food and drug safety ministry, meanwhile, announced it had authorised the Novavax vaccine, which joins the ranks of previously authorised vaccines made by AstraZeneca (NASDAQ:AZN) Inc, Moderna (NASDAQ:MRNA) Inc, Pfizer, and Johnson & Johnson (NYSE:JNJ)'s Janssen.
South Korean vaccine developer SK Bioscience Co Ltd said it will produce the Novavax vaccine.
The two-dose, protein-based vaccine has secured authorisations from European Union regulators and the World Health Organization.
It has been authorised in India, Indonesia and the Philippines, where Novavax's partner, Serum Institute of India, will supply it.
Novavax is awaiting approval in Japan, where its vaccine would be manufactured and distributed by Takeda Pharmaceutical.
At least 84.2% of the country's 52 million population have been fully vaccinated, while 42.5%, have received booster shots, according to health officials.
South Korea added 4,388 new COVID-19 cases as of midnight Tuesday, for a total of 674,868 cases and 6,166 deaths since the pandemic began, the Korea Disease Control and Prevention Agency (KDCA) reported.
That number has dipped from all-time highs of nearly 8,000 daily cases in mid-December, when authorities re-imposed strict social distancing measures to try to stem the tide.
Omicron only accounts for a fraction of South Korea's cases so far, but that percentage has risen to more than 12.5% from 4% at the end of December, health officials said on Wednesday.
Written By: Reuters
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.